Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-05-01
2007-05-01
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100
Reexamination Certificate
active
09805840
ABSTRACT:
Antagonists of alpha 4 integrin/alpha 4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their alpha 4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.
REFERENCES:
patent: 5217870 (1993-06-01), Hession et al.
patent: 5272263 (1993-12-01), Hession et al.
patent: 5367056 (1994-11-01), Hession et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5695755 (1997-12-01), Papayannopoulou
patent: 5824304 (1998-10-01), Papayannopoulou
patent: 5840299 (1998-11-01), Bendig
patent: 5843438 (1998-12-01), Papayannopoulou
patent: 5871734 (1999-02-01), Lobb et al.
patent: 5885786 (1999-03-01), Cabot
patent: 5888507 (1999-03-01), Burkly
patent: 5932214 (1999-08-01), Lobb et al.
patent: 6252043 (2001-06-01), Hession et al.
patent: 6307025 (2001-10-01), Hession et al.
patent: 6602503 (2003-08-01), Lobb et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6692742 (2004-02-01), Nakamura
patent: WO 90/13300 (1990-11-01), None
patent: WO 93/13798 (1993-07-01), None
patent: WO 93/15764 (1993-08-01), None
patent: WO 94/11027 (1994-05-01), None
patent: WO 94/16094 (1994-07-01), None
patent: WO 94/17828 (1994-08-01), None
patent: WO 95/19790 (1995-07-01), None
patent: WO 97/49428 (1997-12-01), None
patent: WO 99/61421 (1999-12-01), None
Lokhorst HM, et al Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 84(7):2269-77, 1994.
van Zaanen HC, et al Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol.;102(3):783-90, Aug. 1998.
Los Alamos National Laboratory web page: http://www.hiv.Ianl.gov/content/immunology/ab—search?action=results;ab—id=706.
Nishinarita et al., “Expression of β1Integrins (Very Late Antigens-4 and -5) on Myeloma Cells and Clinical Correlates in Patients with Multiple Myeloma.”The Journal of International Medical Research, vol. 26, No. 1, pp. 37-42 (Jan./Feb. 1998).
Rodman, “Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma.”Cancer Supplement, vol. 80, No. 8, pp. 1557-1563 (Oct. 15, 1997).
Vidriales, et al., “Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies.”Molecular Medicine Today, vol. 2, pp. 425-431 (Oct. 1996).
Akatsu et al., “Chinese Hamster Ovary Cells Expressing α4β1Integrin Stimulate Osteoclast Formation In Vitro.”Journal of Bone and Mineral Research, vol. 13, No. 8, pp. 1251-1259 (1998).
Barker et al., “The Role of Adhesion Molecules in Multiple Myeloma.”Leukemia and Lymphoma, vol. 8, pp. 189-196 (1992).
Cook et al., “The Role of Adhesion Molecules in Multiple Myeloma.”Acta Hæmatologica; pp. 81-89 (1997).
Fehlner-Gardiner et al., “Differential utilization of VLA-4 (α4β1) and 15(α5β1) integrins during the development of mouse bone marrow-derived mast cells.”Differentiation, vol. 60, No. 4, pp. 317-325 (Jul. 1996).
Masellis-Smith et al., “Adhesion of Multiple Myeloma Peripheral Blood B Cells to Bone Marrow Fibroblasts: A Requirement for CD44 and α4β71.”Cancer Research, vol. 57, No. 5, pp. 930-936 (Mar. 1, 1997).
Michigami et al., “Interactions of Myeloma Cells with Bone Marrow Stromal Cells Via α4β1 Integrin-VCAM-1 is Required for the Development of Osteolysis.”Journal of Bone and Mineral Research, vol. 12, Supp. 1, pp. 104 (Aug. 1997).
Mori et al., “Anti α4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma Marrow Stromal Cell Interactions.”Journal of Bone and Mineral Research, vol. 14, Supp. 1, pp. 1161 (Sep. 1999).
Mundy, “Pathogenesis of Hypercalcaemia of Malignancy.”Clinical Endocrinology, vol. 23, No. 1, pp. 705-714 (Jul. 1985).
Mundy et al., “Bone Destruction and Hypercalcemia in Plasma Cell Myeloma.”Seminars in Oncology, vol. 13, No. 3, pp. 291-299 (Sep. 1986).
Mundy, “Osteopenia.”Disease-a-Month, vol. 33, No. 10, pp. 537-600 (Oct. 1987).
Garcia-Gilla et al., “Analysis of the activation state of α4β1 integrin in human B cell lines derived from myeloma, leukemia or lymphoma.”FEBS Letters, vol. 418, No. 3, pp. 337-340 (Dec. 1997).
Barlogie et al., “Extended survival in advanced and refractory multiple . . . ”, Jul. 15, 2001, Blood, vol. 98(2):492 (abstract).
Berenson et al., “Long-Term Pamidronate Treatment of Advanced Multiple Myeloma . . . ”, Feb. 1998, J. Clin. Oncology, vol. 16 (2):593 (abstract).
Dallas et al., “Ibandronate Reduces Osteolytic Lesions but not Tumor Burden . . . ”, Mar. 1, 1998, Blood, vol. 93(5):1697 (abstract).
Damiano et al., “Integrin-Mediated Drug Resistance in Multiple Myeloma”, 2000, Leukemia and Lymphama, vol. 38 (1-2):71-81.
Damiano et al., “Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins . . . ”, Mar. 1, 1999, Blood, vol. 93(5):1658-1667.
Mittelman et al., “Erythropoietin induces tumor regression and antitumor . . . ”, Aug. 24, 2001, PNAS, vol. 98(9):5181 (abstract).
Mundry et al., “Stromal cells regulate survival of B-lineage leukemic cells . . . ”, Sep. 1, 2000, Blood, vol. 96 (5):1926-1932.
Tinhofer et al., “Expression of functional interleukin-15 receptor and autocrine production . . . ”, Jan. 15, 2000, Blood, vol. 95 (2): 610 (abstract).
Hemler et al., “Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides”,J. Biol. Chem. 262:11478-11485, 1987.
Sanchez-Madrid et al., “VLA-3: A novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization”,Eur. J. Immunol. 16:1343-1349, 1986.
Pulido et al., “Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4”,J. Biol. Chem. 266:10241-10245, 1991.
Amit et al., “Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution,” Science, 233(4765):747-753 (1986).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79(6):1979-83 (Mar. 1982).
Alexanian R. et al., “Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.” JAMA, 208(9):1680-5 (Jun 2, 1969).
Owens, R.J., Young, R.J., “The genetic engineering of monoclonal antibodies,” J. Immunol. Methods, 168(2):149-165 (1994).
Alsina, M. et al., “Development of an In Vivo Model of Human Multiple Myeloma Bone Disease,” Blood, 87:1495-1501 (1996).
Attal, M. et al., “A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma,” N. Engl. J. Med, 335:91-97 (1996).
Atkins C., “Correspondence: High-Dose Chemotherapy in Multiple Myeloma,” N. Engl. J. Med., 335:1844 (1996).
Oivanen, T. M. et al., “Correspondence: High-Dose Chemotherapy in Multiple Myeloma,” N. Engl. J. Med., 335:1844-1845 (1996).
Attal et al., “Correspondence: High-Dose Chemotherapy in Multiple Myeloma - In Reply,” N. Engl. J. Med., 335:1844-1845 (1996).
Bataille, R. et al., “Serum levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias,” J. Clin. Invest., 84:2008-2011 (1989).
Bataille, R. et al., “Mechanisms of Bone Lesions in Multiple Myeloma,” Hematology/Oncology Clinics of North America, 6:285-295 (1992).
Bataille, R. et al., “
Mundy Gregory R.
Yoneda Toshiyuki
Board of Regents , The University of Texas System
Fish & Richardson P.C.
Haddad Maher M.
LandOfFree
Methods of treating multiple myeloma and myeloma-induced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating multiple myeloma and myeloma-induced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating multiple myeloma and myeloma-induced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3811877